CoChat

Selective serotonin 5-HT1A receptor biased agonists elicitdistinct brain activation patterns: a pharmacoMRI study

Open access
Becker, G., Bolbos, R., Costes, N., Redouté, J., Newman-Tancredi, A., Zimmer, L. · 2016 · Scientific Reports
Cited by 55

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

Serotonin 1A (5-HT 1A) receptors are involved in several physiological and pathological processes and constitute therefore an important therapeutic target. The recent pharmacological concept of biased agonism asserts that highly selective agonists can preferentially direct receptor signaling to specific intracellular responses, opening the possibility of drugs targeting a receptor subtype in specific brain regions. The present study brings additional support to this concept thanks to functional magnetic resonance imaging (7 Tesla-fMRI) in anaesthetized rats. Three 5-HT 1A receptor agonists (8-OH-DPAT, F13714 and F15599) and one 5-HT 1A receptor antagonist (MPPF) were compared in terms of influence on the brain blood oxygen level-dependent (BOLD) signal. Our study revealed for the first time contrasting BOLD signal patterns of biased agonists in comparison to a classical agonist and a silent antagonist. By providing functional information on the influence of pharmacological activation of 5-HT 1A receptors in specific brain regions, this neuroimaging approach, translatable to the clinic, promises to be useful in exploring the new concept of biased agonism in neuropsychopharmacology.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/srep26633

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Research works printed but not linked: 54

  1. Pompeiano, M., Palacios, J. M. & Mengod, G. Distribution and cellular localization of mRNA coding for 5-HT1A receptor in the rat brain: correlation with receptor binding. J. Neurosci. 12, 440–453 (1992). · DOI · Paper page
  2. Kia, H. K. et al. Immunocytochemical localization of serotonin1A receptors in the rat central nervous system. J. Comp. Neurol. 365, 289–305 (1996). · DOI · Paper page
  3. Fox, S. H. Non-dopaminergic treatments for motor control in Parkinson’s disease. Drugs 73, 1405–1415 (2013). · DOI
  4. Köhler, S., Cierpinsky, K., Kronenberg, G. & Adli, M. The serotonergic system in the neurobiology of depression: Relevance for novel antidepressants. J. Psychopharmacol. 30, 13–22 (2015). · DOI · Paper page
  5. Blier, P. & Ward, N. M. Is there a role for 5-HT1A agonists in the treatment of depression? Biological Psychiatry 53, 193–203 (2003). · DOI · Paper page
  6. Andrade, R., Huereca, D., Lyons, J. G., Andrade, E. M. & McGregor, K. M. 5-HT 1A Receptor-Mediated Autoinhibition and the Control of Serotonergic Cell Firing. ACS Chem. Neurosci. 6, 1110–1115 (2015). · DOI
  7. Richardson-Jones, J. W. et al. 5-HT1A Autoreceptor Levels Determine Vulnerability to Stress and Response to Antidepressants. Neuron 65, 40–52 (2010). · DOI · Paper page
  8. Haddjeri, N., Blier, P. & de Montigny, C. Long-term antidepressant treatments result in a tonic activation of forebrain 5-HT1A receptors. J. Neurosci. 18, 10150–10156 (1998). · DOI · Paper page
  9. Mamo, D. et al. Differential effects of aripiprazole on D2, 5-HT2 and 5-HT1A receptor occupancy in patients with schizophrenia: A triple tracer PET study. Am. J. Psychiatry 164, 1411–1417 (2007). · DOI · Paper page
  10. Meltzer, H. Y., Li, Z., Kaneda, Y. & Ichikawa, J. Serotonin receptors: Their key role in drugs to treat schizophrenia. Prog. Neuro-Psychopharmacology Biol. Psychiatry 27, 1159–1172 (2003). · DOI · Paper page
  11. Newman-Tancredi, A. The importance of 5-HT1A receptor agonism in antipsychotic drug action: rationale and perspectives. Curr. Opin. Investig. Drugs 11, 802–812 (2010).
  12. Newman-Tancredi, A. & Kleven, M. S. Comparative pharmacology of antipsychotics possessing combined dopamine D 2 and serotonin 5-HT 1A receptor properties. Psychopharmacology (Berl). 216, 451–473 (2011). · DOI
  13. Bliss, T. V. & Collingridge, G. L. A synaptic model of memory: long-term potentiation in the hippocampus. Nature 361, 31–39 (1993). · DOI · Paper page
  14. Schechter, L. E. et al. Lecozotan (SRA-333): A Selective Serotonin 1A Receptor Antagonist That Enhances the Stimulated Release of Glutamate and Acetylcholine in the Hippocampus and Possesses Cognitive-Enhancing Properties. J. Pharmacol. Exp. Ther. 314, 1274–1289 (2005). · DOI
  15. Schechter, L. E., Dawson, L. A. & Harder, J. A. The potential utility of 5-HT1A receptor antagonists in the treatment of cognitive dysfunction associated with Alzheimer s disease. Curr. Pharm. Des. 8, 139–145 (2002). · DOI · Paper page
  16. Bonifati, V., Fabrizio, E., Cipriani, R., Vanacore, N. & Meco, G. Buspirone in levodopa-induced dyskinesias. Clinical neuropharmacology 17, 73–82 (1994). · DOI · Paper page
  17. Kannari, K. et al. [Tandospirone citrate, a selective 5-HT1A agonist, alleviates L-DOPA-induced dyskinesia in patients with Parkinson’s disease]. No To Shinkei 54, 133–137 (2002).
  18. Levitt, E. S., Hunnicutt, B. J., Knopp, S. J., Williams, J. T. & Bissonnette, J. M. A selective 5-HT1A receptor agonist improves respiration in a mouse model of Rett syndrome. J. Appl. Physiol. 115, 1626–1633 (2013). · DOI
  19. Newman-Tancredi, A. Biased agonism at serotonin 5-HT1A receptors: Preferential postsynaptic activity for improved therapy of CNS disorders. Neuropsychiatry (London). 1, 149–164 (2011). · DOI · Paper page
  20. Lefkowitz, R. J. & Shenoy, S. K. Transduction of receptor signals by beta-arrestins. Science 308, 512–517 (2005). · DOI · Paper page
  21. Reiter, E., Ahn, S., Shukla, A. K. & Lefkowitz, R. J. Molecular mechanism of β-arrestin-biased agonism at seven-transmembrane receptors. Annu. Rev. Pharmacol. Toxicol. 52, 179–97 (2012). · DOI · Paper page
  22. Kenakin, T. P. Biased signalling and allosteric machines: New vistas and challenges for drug discovery. British Journal of Pharmacology 165, 1659–1669 (2012). · DOI · Paper page
  23. Mannoury la Cour, C. et al. Regional Differences in the Coupling of 5-Hydroxytryptamine- 1A Receptors to G Proteins in the Rat Brain. Mol. Pharmacol. 70, 1013–1021 (2006). · DOI
  24. Buritova, J., Berrichon, G., Cathala, C., Colpaert, F. & Cussac, D. Region-specific changes in 5-HT1A agonist-induced Extracellular signal-Regulated Kinases 1/2 phosphorylation in rat brain: a quantitative ELISA study. Neuropharmacology 56, 350–61 (2009). · DOI
  25. Maurel, J. L. et al. High-efficacy 5-HT1A agonists for antidepressant treatment: A renewed opportunity. J. Med. Chem. 50, 5024–5033 (2007). · DOI
  26. Assié, M.-B., Lomenech, H., Ravailhe, V., Faucillon, V. & Newman-Tancredi, A. Rapid desensitization of somatodendritic 5-HT 1A receptors by chronic administration of the high- efficacy 5-HT 1A agonist, F13714: a microdialysis study in the rat. Br. J. Pharmacol. 149, 170–178 (2006). · DOI · Paper page
  27. Newman-Tancredi, A. et al. Signal transduction and functional selectivity of F15599, a preferential post-synaptic 5-HT 1A receptor agonist. Br. J. Pharmacol. 156, 338–353 (2009). · DOI · Paper page
  28. Llado-Pelfort, L., Assie, M. B., Newman-Tancredi, A., Artigas, F. & Celada, P. Preferential in vivo action of F15599, a novel 5-HT1A receptor agonist, at postsynaptic 5-HT1A receptors. Br. J. Pharmacol. 160, 1929–1940 (2010). · DOI · Paper page
  29. Schwarz, A. J., Gozzi, A., Reese, T. & Bifone, A. In vivo mapping of functional connectivity in neurotransmitter systems using pharmacological MRI. Neuroimage 34, 1627–1636 (2007). · DOI
  30. Martin, C. & Sibson, N. R. Pharmacological MRI in animal models: A useful tool for 5-HT research? Neuropharmacology 55, 1038–1047 (2008). · DOI
  31. Anderson, I. M., McKie, S., Elliott, R., Williams, S. R. & Deakin, J. F. W. Assessing human 5-HT function in vivo with pharmacoMRI. Neuropharmacology 55, 1029–1037 (2008). · DOI
  32. Bifone, A. & Gozzi, A. Neuromapping techniques in drug discovery: pharmacological MRI for the assessment of novel antipsychotics. Expert Opin. Drug Discov. 7, 1071–1082 (2012). · DOI
  33. Arthurs, O. J. & Boniface, S. How well do we understand the neural origins of the fMRI BOLD signal? Trends in Neurosciences 25, 27–31 (2002). · DOI · Paper page
  34. Masamoto, K., Kim, T., Fukuda, M., Wang, P. & Kim, S. G. Relationship between neural, vascular and BOLD signals in isoflurane-anesthetized rat somatosensory cortex. Cereb. Cortex 17, 942–950 (2007). · DOI · Paper page
  35. Sicard, K. et al. Regional cerebral blood flow and BOLD responses in conscious and anesthetized rats under basal and hypercapnic conditions: implications for functional MRI studies. J. Cereb. Blood Flow Metab. 23, 472–81 (2003). · DOI · Paper page
  36. Assié, M.-B. et al. F15599, a highly selective post-synaptic 5-HT (1A) receptor agonist: in-vivo profile in behavioural models of antidepressant and serotonergic activity. Int. J. Neuropsychopharmacol. 13, 1285–1298 (2010). · DOI · Paper page
  37. Horiguchi, M. & Meltzer, H. Y. The role of 5-HT1A receptors in phencyclidine (PCP)-induced novel object recognition (NOR) deficit in rats. Psychopharmacology (Berl). 221, 205–215 (2012). · DOI
  38. Depoortère, R. et al. F15599, a preferential post-synaptic 5-HT1A receptor agonist: activity in models of cognition in comparison with reference 5-HT1A receptor agonists. Eur. Neuropsychopharmacol. 20, 641–654 (2010). · DOI
  39. Iderberg, H., McCreary, A. C., Varney, M. A., Cenci, M. A. & Newman-Tancredi, A. Activity of serotonin 5-HT1A receptor ‘biased agonists’ in rat models of Parkinson’s disease and l-DOPA-induced dyskinesia. Neuropharmacology 93, 52–67 (2015). · DOI
  40. Assie, M. B., Ravailhe, V., Faucillon, V. & Newman-Tancredi, A. Contrasting contribution of 5-hydroxytryptamine 1A receptor activation to neurochemical profile of novel antipsychotics: frontocortical dopamine and hippocampal serotonin release in rat brain. J. Pharmacol. Exp. Ther. 315, 265–272 (2005). · DOI
  41. Koek, W. et al. 5-HT1A receptor activation and antidepressant-like effects: F 13714 has high efficacy and marked antidepressant potential. Eur. J. Pharmacol. 420, 103–112 (2001). · DOI
  42. Assié, M. B. & Koek, W. Possible in vivo 5-HT reuptake blocking properties of 8-OH-DPAT assessed by measuring hippocampal extracellular 5-HT using microdialysis in rats. Br. J. Pharmacol. 119, 845–50 (1996). · DOI · Paper page
  43. Kung, M. P., Frederick, D., Mu, M., Zhuang, Z. P. & Kung, H. F. 4-(2′-Methoxy-phenyl)-1-[2′-(n-2″-pyridinyl)-p-iodobenzamido]-ethyl- piperazine ([125I]p-MPPI) as a new selective radioligand of serotonin-1A sites in rat brain: in vitro binding and autoradiographic studies. J. Pharmacol. Exp. Ther. 272, 429–437 (1995).
  44. Zhuang, Z. P., Kung, M. P. & Kung, H. F. Synthesis and evaluation of 4-(2′-methoxyphenyl)-1-[2′-[N-(2″-pyridinyl)-p- iodobenzamido]ethyl]piperazine (p-MPPI): a new iodinated 5-HT1A ligand. J Med Chem 13, 1406–1407 (1994). · doi:10.1021/jm00036a003
  45. Sprouse, J., Reynolds, L., Li, X., Braselton, J. & Schmidt, A. 8-OH-DPAT as a 5-HT7 agonist: Phase shifts of the circadian biological clock through increases in cAMP production. Neuropharmacology 46, 52–62 (2004). · DOI
  46. Lovenberg, T. W. et al. A novel adenylyl cyclase-activating serotonin receptor (5-HT7) implicated in the regulation of mammalian circadian rhythms. Neuron 11, 449–458 (1993). · DOI · Paper page
  47. Canese, R. et al. Differential response to specific 5-Ht (7) versus whole-serotonergic drugs in rat forebrains: A phMRI study. Neuroimage 58, 885–894 (2011). · DOI
  48. Lemoine, L. et al. F15599, a novel 5-HT1A receptor agonist, as a radioligand for PET neuroimaging. Eur. J. Nucl. Med. Mol. Imaging 37, 594–605 (2010). · doi:10.1007/s00259-009-1274-y
  49. Vacher, B. et al. Novel derivatives of 2-pyridinemethylamine as selective, potent and orally active agonists at 5-HT(1A) receptors. J. Med. Chem. 42, 1648–1660 (1999). · DOI
  50. Van Goethem, N. P., Schreiber, R., Newman-Tancredi, A., Varney, M. & Prickaerts, J. Divergent effects of the ‘biased’ 5-HT1A receptor agonists F15599 and F13714 in a novel object pattern separation task. Br. J. Pharmacol. 172, 2532–2543 (2015). · DOI
  51. Carli, M. & Samanin, R. 8-Hydroxy-2-(di-n-propylamino)tetralin impairs spatial learning in a water maze: role of postsynaptic 5-HT1A receptors. Br. J. Pharmacol. 105, 720–6 (1992). · DOI · Paper page
  52. Paxinos, G. & Watson, C. The Rat Brain in Stereotaxic Coordinates Sixth Edition by. Acad. Press170, 547612 (2006).
  53. Lancelot, S. et al. A multi-atlas based method for automated anatomical rat brain MRI segmentation and extraction of PET activity. PLoS One 9, 9(10):e109113; doi: 10.1371/journal.pone.0109113 (2014). · DOI
  54. McKie, S. et al. Neuronal effects of acute citalopram detected by pharmacoMRI. Psychopharmacology (>Berl). 180, 680–686 (2005). · DOI

Cited by

Metadata

Authors
Becker, G., Bolbos, R., Costes, N., Redouté, J., Newman-Tancredi, A., & Zimmer, L.
Venue
Scientific Reports
Published
2016-05-23
Volume
6
Issue
1
Pages
26633-26633
ISSN
2045-2322 (ISSN-L)
OpenAlex
W2396454338
Cited by
55
References
1
FWCI
3.75
Type
journal article
Language
en
Open access
gold
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.